Table of contents

Clinical/translational cancer immunotherapy

• Original research: TGM4: an immunogenic prostate-restricted antigen (30 June, 2021)

  Zoila A Lopez-Bujanda, Aleksandar Obradovic, Thomas R Nirschl, Laura Crowley, Rodney Macedo, Alexandros Papachristodoulou, Timothy O’Donnell, Uri Laserson, Jelani C Zarif, Ran Reshef, Tiezheng Yuan, Mithil K Soni, Emmanuel S Antonarakis, Michael C Haffner, H Benjamin Larman, Michael M Shen, Pawel Muranski, Charles G Drake
• Original research: Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice (25 June, 2021)

  Alexander A Pieper, Alexander L Rakhmilevich, Daniel V Spiegelman, Ravi B Patel, Jen Birstler, Won Jong Jin, Peter M Carlson, Deborah H Charych, Jacquelyn A Hank, Amy K Erbe, Willem W Overwijk, Zachary S Morris, Paul M Sondel
• Original research: Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy (25 June, 2021)

  Hannah Reimann, Andrew Nguyen, J Zachary Sanborn, Charles J Vaske, Stephen C Benz, Kayvan Niazi, Shahrooz Rabizadeh, Patricia Spilman, Andreas Mackensen, Matthias Ruebner, Alexander Hein, Matthias W Beckmann, Edith D van der Meijden, Judith Bausenwein, Sascha Kretschmann, Marieke Griffioen, Jeffrey Schlom, James L Gulley, Karin L Lee, Duane H Hamilton, Patrick Soon-Shiong, Peter A Fasching, Anita N. Kremer
• Original research: Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma (24 June, 2021)

  Haijing Deng, Anna Kan, Ning Lyu, Meng He, Xin Huang, Shuang Qiao, Shaolong Li, Wenhua Lu, Qiankun Xie, Huiming Chen, Jinfa Lai, Qifeng Chen, Xiongying Jiang, Shousheng Liu, Zhenfeng Zhang, Ming Zhao
• Original research: Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial (24 June, 2021)

  Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, Nicky D’Haene, Alex Michotte, Ben Caljon, Isabelle Salmon, Michaël Bruneau, Mark Kockx, Sonia Van Dooren, Anne-Marie Vanbinst, Hendrik Everaert, Ramses Forsyth, Bart Neyns
• Original research: Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis (23 June, 2021)

  Igor Puzanov, Poornima Subramanian, Yan V Yatsynovich, David M Jacobs, Maya R Chilbert, Umesh C Sharma, Fumito Ito, Steven G Feuerstein, Filip Stefanovic, Benjamin Switzer, Mark D Hicar, Anne B Curtis, Edward J Spangenthal, Grace K Dy, Marc S Ernstoff, Pankit Vachhani, Brian J Page, Nikhil Agrawal, Arjun Khunger, Ankita Kapoor, Alexander Hattoum, Jerome J Schentag
• Original research: Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study (22 June, 2021)

  Joseph Sleiman, Wei Wei, Ravi Shah, Muhammad Salman Faisal, Jessica Philpott, Pauline Funchain
• Original research: Pericardial disease in patients treated with immune checkpoint inhibitors (18 June, 2021)

  Jingyi Gong, Zsofia Dora Drobni, Amna Zafar, Thiago Quinaglia, Sarah Hartmann, Hannah K Gilman, Vineet K Raghu, Carlos Gongora, Meghan E Sise, Raza M Alvi, Leyre Zubiri, Anju Nohria, Ryan Sullivan, Kerry L Reynolds, Daniel Zlotoff, Tomas G Neilan
• Original research: Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors (14 June, 2021)

  Murtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, Shaheen Khan, Farjana Fattah, Jason Y Park, Vinita Popat, Jessica M Saltarski, Yvonne Gloria-McCutchen, David Hsiehchen, Jared Ostmeyer, Saad A Khan, Nazima Sultana, Yang Xie, Quan-Zhen Li, Edward K Wakeland, David E Gerber
• Original research: Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer (11 June, 2021)

  Lawrence G. Lum, Zaid Al-Kadhimi, Abhinav Deol, Vidya Kondadasula, Dana Schalk, Elyse Tomashewski, Patricia Steele, Kristie Fields, Melissa Giroux, Qin Liu, Lawrence Flaherty, Michael Simon, Archana Thakur
• Original research: Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma (11 June, 2021)

  Yousef Zakharia, Robert R McWilliams, Olivier Rixe, Joseph Drabick, Montaser F Shaheen, Kenneth F Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses Sadek, Lucinda L Tennant, Christopher M Smith, Eugene P Kennedy, Charles J Link Jr, Nicholas N Vahanian, Jiayi Yu, Steven S Shen, Erik L Brincks, Gabriela R Rossi, David Munn, Mohammed Milhem
• Original research: Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2 (10 June, 2021)

  Giulia Pellizzari, Olivier Martinez, Silvia Crescioli, Robert Page, Ashley Di Meo, Silvia Mele, Giulia Chiaruttini, Jan Hoinka, Ihor Batruch, Ioannis Prassas, Melanie Grandits, Jacobo López-Abente, Eva Bugallo-Blanco, Malcolm Ward, Heather J Bax, Elise French, Anthony Cheung, Sara Lombardi, Mariangela Figini, Katie E Lacy, Eleftherios P Diamandis, Debra H Josephs, James Spicer, Sophie Papa, Sophia N Karagiannis
• Original research: Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial (8 June, 2021)

  Yoland Antill, Peey-Sei Kok, Kristy Robledo, Sonia Yip, Michelle Cummins, Deborah Smith, Amanda Spurdle, Elizabeth Barnes, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, John Andrews, Martin R Stockler, Linda Mileshkin
• Original research: Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients (4 June, 2021)

  Alexandre Gérard, Jerome Doyen, Marion Cremoni, Laurent Bailly, Kevin Zorzi, Caroline Ruetsch-Chelli, Vesna Brglez, Alexandra Picard-Gauci, Laura Troin, Vincent L.M. Esnault, Thierry Passeron, Henri Montaudié, Barbara Seitz-Polski
• Original research: Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release (4 June, 2021)

  Kevin Dang, Giulia Castello, Starlynn C Clarke, Yuping Li, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E Harris, Duy Pham, Preethi Sankaran, Harshad S Ugamraj, Rong Deng, Serena Kwek, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D Trinklein, Roland Buelow, Ben Buelow, Lawrence Fong, Pranjali Dalvi
• Original research: Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors (4 June, 2021)

  Daan P. Hurkmans, Sebastiaan D.T. Sassen, Karlijn de Joode, Lisanne Putter, Edwin A. Basak, Annemarie J.M. Wijkhuijs, Markus Joerger, Reno Debets, Birgit C.P. Koch, Cor H. Van der Leest, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen
• Original research: Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer (3 June, 2021)

  Quentin Klopfenstein, Valentin Derangère, Laurent Arnould, Marion Thibaudin, Emeric Limagne, Francois Ghiringhelli, Caroline Truntzer, Sylvain Ladoire
• Original research: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial (2 June, 2021)

  Robert L Ferris, William C Spanos, Rom Leidner, Anthony Gonçalves, Uwe M Martens, Chrisann Kyi, William Sharfman, Christine H Chung, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Lazar Vujanovic, Janis M Taube, Julie E Stein, Jun Li, Bin Li, Tian Chen, Adam Barrows, Suzanne L Topalian